Advances in Pharmacokinetics and Pharmacodynamics

ISBN-13: 9783031295409 / Angielski

Panos Macheras

Opis

This book provides a concise overview of recent advances in Pharmacokinetics (PK) and Pharmacodynamics (PD). The pharmacokinetics section covers the state of the art inPhysiologically Based Pharmacokinetic (PBPK) modeling (Chapter 1) as well as the assessment of food effect on drug absorption using PBPK modeling (Chapter 2). Chapters 3 and 4 describe the recent development ofPhysiologically Based Finite Time Pharmacokinetic (PBFTPK) models and
their applications to pharmacokinetic data. The pharmacodynamics section focuses on PK/PD modeling. Chapter 5 providesan overview of PK/PD modeling and simulation in clinical practice and
studies. Chapter 6 deals with the subject/physiology variability issue encountered in PK/PD studies, while Chapter 7 reviews the influence ofclinical pharmacology in the modernization of drug development and regulation. This book is an essential reference for pharmaceutical scientists.

Spis treści

Pharmacokinetics

1. Current status in PBPK modeling.

Ryuta Asaumi, Kiyohiko Sugano, Ritsumeikan University, Japan suganok@fc.ritsumei.ac.jp

2. Physiologically based biopharmaceutics modeling (PBBM) Application on Food Effect Assessment.

Di Wu, John P. Gleeson, Filippos Kesisoglou, Biopharmaceutics Group, Merck, New Jersey, USA filippos_kesisoglou@merck.com

3. Physiologically based finite time pharmacokinetic (PBFTPK) models: Inception and development

Athanasios A. Tsekouras and Panos Macheras, National and Kapodistrian University of Athens, Greece macheras@pharm.uoa.gr

4. Physiologically based finite time pharmacokinetic (PBFTPK) models: Applications

Athanasios A. Tsekouras, Nikos Alimpertis, and Panos Macheras, National and Kapodistrian University of Athens, Greece macheras@pharm.uoa.gr

Pharmacodynamics

5. Pharmacokinetic – Pharmacodynamic Modelling and Simulation in Clinical Practice and Studies

Thomas P.C. Dorlo & Elin M. Svensson tdorlo@page-meeting.org

6. On the Verge of Impossibility: Accounting for Variability Arising from Permutations of Comorbidities that Affect the Fate of Drugs in the Human Body.

Amin Rostami-Hodjegan, University of Manchester, Vice President of Research & Development at Simcyp Ltd (a Certara Company) amin.rostami@manchester.ac.uk and Brahim Achour brahim.achour@manchester.ac.uk

7. Impact of Clinical Pharmacology on the Modernization of Drug Development and RegulationCarl Peck ccpeck@icloud.com and Liang Zhao liang.zhao@fda.hhs.gov

O autorze

Panos Macheras is Emeritus Professor (since September 2014) of the Department of Pharmacy, University of Athens.  He is the Founder (1of the Laboratory of Biopharmaceutics and Pharmacokinetics at the University of Athens. He established  the PharmaInformatics Unit of the Research and Innovation Center ATHENA; he is currently the Head of the Unit.Adjunct Professor, Department of Pharmaceutical Sciences, State University of New York (SUNY), Buffalo, USA He received his B. Pharm. and Ph.D degree in Pharmaceutical Chemistry from the University of Athens, Greece.  He also received a Ph.D degree  in Biopharmaceutics-Pharmacokinetics from King's College, University of London, U.K. He has published more than 180 journal articles (more than 6500 citations, h=40) and seven books in the field of Biopharmaceutics-Pharmacokinetics-Pharmacodynamics. His research interests include experimental, theoretical and computational (modeling and simulation) studies on drug dissolution, release, gastrointestinal absorption, protein binding, drug-cyclodextrins interaction, bioequivalence, biopharmaceuitc classification of drugs, pharmacokinetics, fractal and fractional kinetics, applications of fractal concepts in biopharmaceutical systems and nonlinear dynamics. He serves on the Editorial Board of the journals, Pharmaceutical Research, International Journal of Pharmaceutics and European Journal of Pharmaceutical Sciences.